Search Results

UAB startup LifeNuclear launches TheraGuide, a radiation safety guidance platform for radiopharmaceutical therapy

On August 7, LifeNuclear, a medical technology startup incubated by the University of Alabama at Birmingham (UAB), announced the launch of TheraGuide, a digital platform designed to help patients undergoing radiopharmaceutical cancer treatment understand and follow radiation safety guidance after discharge. Radiopharmaceutical therapy uses radioactive drugs to target cancer cells while minimizing damage to surrounding healthy tissue. As the therapy's applications expand, patients are typically required to read and follow complex written instructions after treatment, which can be difficult for some patients and caregivers to understand and execute. Dr. Remo George LifeNuclear was founded by UAB...

2026-08-08

228 Research Reactors Worldwide in Operation, Supporting Medical Isotope Production and Neutron Science Innovation

According to the International Atomic Energy Agency on August 7, research reactors continue to drive innovation in science, medicine, and industry worldwide. Currently, 228 research reactors are in operation across 54 countries, with another 23 under construction or in the planning stage. Unlike nuclear reactors used for power generation, these reactors primarily produce neutrons to support medical, industrial, agricultural, geological, forensic, and nuclear science research. A research reactor pool photographed from above. (Photo: IAEA) In the medical field, research reactors are a vital source of medical radioisotopes. Among them, technetium-99m is widely used for diagnosing cancer and diseases of the heart, brain, and bones; a large number of medical diagnostic and therapeutic procedures worldwide rely on this isotope. Other radioisotopes such as iodine-131 are also used in the treatment of cancer and thyroid diseases. The IAEA states that radioisotopes produced by research reactors serve millions of patients globally and are an essential component of modern nuclear medicine systems.

2026-08-09

Cancer Cryoablation Treatments at Southeast Region Nuclear Medicine Center in Korea Exceed 100 Cases

The Southeast Region Nuclear Medicine Center announced on August 8 that since introducing cancer cryoablation in 2024, the center has completed over 100 related procedures, providing treatment to a total of 104 cancer patients. Cryoablation is a minimally invasive tumor treatment method. During the procedure, doctors insert a thin treatment needle precisely into the tumor site under CT or ultrasound imaging guidance, freezing the lesion at ultra-low temperatures of minus 40 degrees Celsius or lower to cause cancer cell necrosis. As the low-temperature freezing itself has a certain anesthetic effect, this technique helps reduce patient pain, minimize damage to surrounding normal tissues, and promote faster postoperative recovery. According to the center, among the patients treated so far, there are 58 cases of liver cancer and liver metastases, 17 cases of primary lung cancer, recurrent lung cancer, and lung metastases, and 29 cases of renal cancer. Among them, 8 patients underwent treatment for two lesions simultaneously in a single procedure. Liver...

2026-08-08

CNNC Fuzhi Officially Established, CNNC Isotope Holds 90% Stake to Integrate the Full Nuclear Medicine Industry Chain

On August 6, 2026, CNNC Fuzhi (Beijing) Technology Co., Ltd. (hereinafter referred to as "CNNC Fuzhi") was officially established. The company was jointly funded by CNNC Isotope Co., Ltd. (hereinafter referred to as "CNNC Isotope") and CNNC (Zhejiang) Innovation Co., Ltd. (hereinafter referred to as "CNNC Zhejiang Innovation"), with CNNC Isotope holding 90% of the shares and CNNC Zhejiang Innovation holding 10%. CNNC Fuzhi will take over the business of CNNC Isotope's Nuclear Medicine Development Center, focusing on deep cultivation in the smart nuclear medicine sector. With the smart nuclear medicine IoT system as its core carrier, the company aims to integrate the entire nuclear medicine industry chain, build a synergistic development model of "smart nuclear medicine system + nuclear drugs + equipment + services," and drive the business transition from single product supply to full value chain integration...

2026-08-08

Institute of Radiation Medicine, Chinese Academy of Medical Sciences Hosts Academic Seminar on PSMA-Targeted Radiopharmaceuticals

On August 3, the Institute of Radiation Medicine, Chinese Academy of Medical Sciences held an academic seminar, inviting Professor Lin Guoxian from the BC Cancer Agency in Vancouver, Canada, to deliver a lecture titled "Development of Prostate-Specific Membrane Antigen-Targeted Radiopharmaceuticals for the Diagnosis and Treatment of Prostate Cancer." The seminar was held in a hybrid format, with some researchers and graduate students from the institute attending in person. Professor Lin Guoxian has long been engaged in the development of targeted radiopharmaceuticals for cancer diagnosis and therapy, having led or contributed to the publication of over 135 peer-reviewed journal articles, filed more than 30 patent applications related to radiopharmaceuticals, and completed clinical translation of 7 self-developed radiopharmaceuticals applied in...

2026-08-07

First Validation of Novel PRI Technology: Existing PET Tracers Can Image Tissue Microenvironment

August 6, 2026 - A joint research team from the Graduate School of Engineering at the University of Tokyo and the University of York in the UK announced that they have established a novel geometric imaging principle utilizing positron three-photon decay and successfully validated Positronium Ratio Imaging (PRI) technology for the first time. This method can be used in conjunction with existing clinical PET tracers and is expected to provide a new means of observing tissue microenvironments in nuclear medicine imaging. Conceptual diagram of next-generation nuclear medicine imaging utilizing positron-3-photon decay. Current clinical PET scans primarily rely on the positron two-photon annihilation process to visualize the distribution and accumulation of tracers in the body, but they provide limited information on microenvironmental factors such as tissue hypoxia that are associated with disease malignancy...

2026-08-07

Construction of Proton Therapy Center in Ulsan, South Korea Faces Hurdles: Government Funding Allocation Adjustments Impact Project Progress

The proton therapy center construction project in Ulsan, South Korea, has recently encountered obstacles to progress. The project was once regarded as a key component in improving the regional cancer treatment system in southeastern South Korea, but due to shifts in government medical financial support priorities, the difficulty of securing large-scale national funding independently has increased significantly. According to information from Ulsan City on August 6, Ulsan City completed the feasibility study and basic planning services for the proton therapy center construction in March of last year and began seeking national funding. However, the Ministry of Health and Welfare responded that it would be difficult to provide large-scale project funding to Ulsan City alone. Previously, Ulsan City had planned to establish a proton therapy center to build a system enabling cancer patients to undergo surgery...

2026-08-07

Japanese PET Study Suggests Late-Onset Psychosis May Be Linked to Neurodegenerative Pathology

A nuclear medicine imaging study conducted by a Japanese research team has shown that many adults who experience psychotic symptoms such as hallucinations and delusions for the first time after age 40 have abnormal protein deposits in the brain associated with Alzheimer's disease and other neurodegenerative disorders. The study included 37 patients with late-onset psychosis and 47 age-matched healthy controls. The researchers used the amyloid PET tracer ^11C-PiB and the tau protein PET tracer ^18F-florzolotau to assess the accumulation of β-amyloid and tau proteins in the participants' brains. The results showed that among patients with late-onset psychosis, β-amyloid positivity...

2026-08-06

Thor Medical Commences Commercial Supply with First Delivery of High-Purity Thorium-228 from AlphaOne

Thor Medical ASA announced on August 5 that it has completed the first customer delivery of high-purity thorium-228 (Th-228) from its AlphaOne production facility at the Herøya industrial park. This marks the first customer shipment following the facility's production start announced last week, and signifies AlphaOne's entry into the commercial supply phase. Thor Medical CEO Jasper Kurth stated that commercial production represents the beginning of the company's industrial-scale manufacturing, and the first customer delivery demonstrates the company's transition from capacity building to serving customers through its first industrial-scale facility. The company stated that as production capacity gradually ramps up, it will continue to meet the growing demand for high-purity isotopes in the targeted alpha therapy field...

2026-08-06

Quantum X Labs Advances Quantum Computing for Nuclear Particle Transport Predictive Simulations

Quantum X Labs Inc. recently announced that its subsidiary, Nuclear Quantum, has proposed a new solution to a bottleneck in computational simulations for the nuclear industry, attempting to introduce quantum computing into nuclear particle transport prediction to support compute-intensive scenarios such as nuclear medicine system design. According to reports, traditional particle transport simulations play an important role in nuclear medicine system design, but they often require substantial computational resources and involve long runtimes, impacting R&D and optimization efficiency. The technology proposed by Nuclear Quantum aims to transform physical transport models into quantum circuits, enabling particle propagation and random walk dynamics to be directly represented and simulated within a quantum computing framework...

2026-08-06

South Korea advances plan to produce medical isotopes using nuclear power plants, with lutetium-177 targeted for commercial production in 2031

South Korea is advancing plans to industrialize the production of radioisotopes using nuclear power plants, with the medical isotope lutetium-177 (Lu-177) designated as the first commercial target product. Korea Hydro & Nuclear Power stated that it plans to prioritize the commercialization of Lu-177 production, with the potential to later expand the product range to include isotopes such as cobalt-60, tritium-3, and helium-3. Lu-177 is a therapeutic radioisotope widely used in the global radiopharmaceutical market, applicable in radiopharmaceuticals for diseases such as prostate cancer and neuroendocrine tumors. Previously, South Korea relied entirely on imports for its Lu-177 supply. Due to its half-life of approximately 6.6 days, the entire process from production and transportation to drug preparation and patient administration...

2026-08-06

Han Bing, Chairman of Hefei Municipal CPPCC, Leads Delegation to CYC Ion for Research and Guidance

On the afternoon of August 4, Han Bing, Chairman of Hefei Municipal Committee of the Chinese People's Political Consultative Conference (CPPCC), led a delegation to CYC Ion for research and guidance, and held a symposium. Yong Fengshan, Deputy Director of the Standing Committee of the Municipal People's Congress; Su Xiang, Secretary-General of the Municipal CPPCC; Jiang Xin, Chairman of the Municipal Industrial Investment Group; Zhang Xiaofeng, Director of the Education, Science, Health and Sports Committee of the Municipal CPPCC; and Guo Mei, Deputy Director of the Municipal Bureau of Industry and Information Technology, participated in the event. Song Yuntao, Deputy Director of the Hefei Institutes of Physical Science, Chinese Academy of Sciences; Liu Lu, Chairman of CYC Ion; Chen Yonghua, General Manager; and Deputy General Managers Ding Kaizhong, Li Jun, and Guang Ruohuai accompanied the delegation. The delegation was briefed in detail on CYC Ion's industrial layout and business operations, with discussions focusing on key technological breakthroughs in nuclear medicine and high-end equipment, technology transfer and commercialization, and industrial development.

2026-08-06

CNNC & CIR Co-sponsors Regional Nuclear Medicine Department Development Training Program (Ganzhou Session) and Ganzhou Cancer Hospital High-Quality Nuclear Medicine Diagnosis and Treatment Project Launched Simultaneously

Recently, the Regional Nuclear Medicine Department Development Training Program (Ganzhou Session) and the Ganzhou Cancer Hospital High-Quality Nuclear Medicine Diagnosis and Treatment Project were launched simultaneously at Ganzhou Cancer Hospital. An expert panel from the Nuclear Medicine Branch of the Chinese Medical Association, along with representatives from CNNC & CIR and Atom High-Tech, visited the hospital for research and exchange. More than 200 medical staff from medical institutions at various levels across Jiangxi Province attended the event. The launch ceremony was moderated by Yang Chuansheng, Director of the Nuclear Medicine Department at Ganzhou Cancer Hospital. Fu Wei, Deputy Director of the Ganzhou Municipal Health Commission; Wang Jing, Chair of the Nuclear Medicine Branch of the Chinese Medical Association; and Huang Xingwei, Party Secretary of Ganzhou Cancer Hospital, attended and delivered speeches. Wang Jing stated that nuclear medicine plays a vital supporting role in the precise diagnosis and treatment of major diseases such as cancer, and that promoting the standardized development of regional nuclear medicine at the city and county levels is conducive to channeling high-quality medical resources to the grassroots and enhancing primary healthcare service capabilities.

2026-08-06

Zhang Yiming, Chairman of HTA: Tackling the "Last Mile" of Nuclear Pharmacy Network Delivery to Bring Domestic Radiopharmaceuticals to Patients in Western and County-Level Regions

On July 28, the 2026 Radiopharmaceutical Innovation and Development Conference was held in Taiyuan, Shanxi Province. Zhang Yiming, Party Committee Secretary and Chairman of HTA, told reporters that the company is restructuring its short half-life radiopharmaceutical delivery system through "regional layout + standardized logistics + grassroots empowerment," striving to ensure that cancer patients in western and county-level regions can access domestically produced radiopharmaceuticals within the drug's effective half-life window. Currently, multi-dimensional policy dividends are being continuously released, and China's radiopharmaceutical industry is entering a critical window of opportunity. Alpha nuclide drugs represent the future direction of therapeutic radiopharmaceuticals. Zhang Yiming introduced that HTA has already made early arrangements for drug research in this field, jointly conducting research on actinium-225 labeled...

2026-08-05

Samsung and Accuray Plan Collaboration on Image-Guided Precision Radiation Therapy

Samsung Electronics' medical device business and Samsung Medison continue to shift their business focus from medical diagnostics to treatment. On August 5, Samsung HME America and U.S. radiosurgery company Accuray announced the signing of a non-binding letter of intent to explore collaboration on volume imaging-based precision radiation therapy solutions. Under the letter of intent, the two parties plan to study the integration of Samsung's mobile CT scanner BodyTom with Accuray's robotic radiosurgery platform CyberKnife. This collaboration direction aims to connect high-resolution 3D imaging capabilities with image-guided robotic radiosurgery technology, enabling medical staff to more accurately identify...

2026-08-05